Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Bralten, Linda B ^a   Nouwens, Stephan ^a   Kockx, Christel ^a   Erdem, Lale ^a   Hoogenraad, Casper C ^a   Kros, Johan M ^a   Moorhouse, Michael J ^a   Smitt, Peter A Sillevis ^a   van der Spek, Peter ^a   van Ijcken, Wilfred ^a   Stubbs, Andrew ^a   French, Pim J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; PDZ PROTEIN; ARHGEF16 PROTEIN, HUMAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR;

ADULT; ARHGEF16 GENE; ARTICLE; BINDING AFFINITY; BINDING SITE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCATION; GENE TARGETING; GENETIC HETEROGENEITY; HUMAN; MALE; MICROARRAY ANALYSIS; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; RNA SEQUENCE; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; CHROMOSOME 1; CHROMOSOME 19; CPG ISLAND; DNA METHYLATION; GENETIC ASSOCIATION; GENETICS; MUTATION; TUMOR GENE;

ADULT; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CPG ISLANDS; DNA METHYLATION; FEMALE; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MALE; MUTATION; OLIGODENDROGLIOMA; PROMOTER REGIONS, GENETIC;

EID: 79960062819     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022000     Document Type: Article

References (36)

1. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, et al. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479.
2. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, et al. (2003) Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64: 271-278.
3. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, et al. (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21: 2525-2528.
4. French PJ, Swagemakers SMA, Nagel JHA, Kouwenhoven MCM, Brouwer E, et al. (2005) Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 65: 11335-11344.
5. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, et al. (2007) Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 67: 5635-5642.
6. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, et al. (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69: 9065-9072.
7. Bralten LB, Kloosterhof NK, Gravendeel LA, Sacchetti A, Duijm EJ, et al. (2010) Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. Genes Chromosomes Cancer 49: 507-517.
8. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, et al. (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97: 1276-1284.
9. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, et al. (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8: 196-201.
10. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, et al. (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5048-5050.
11. Ohgaki H, Kleihues P, (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489.
12. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
13. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, et al. (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474.
14. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ, (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 12: 83-89.
15. Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, et al. (2010) Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 31: E1186-1199.
16. Knudson AG Jr, (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823.
17. Weinstein IB, Joe A, (2008) Oncogene addiction. Cancer Res 68: 3077-3080; discussion.
18. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288.
19. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
20. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M, (2005) Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11: 1119-1128.
21. Alaminos M, Davalos V, Ropero S, Setien F, Paz MF, et al. (2005) EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 65: 2565-2571.
22. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, et al. (2007) CHD5 is a tumor suppressor at human 1p36. Cell 128: 459-475.
23. Riemenschneider MJ, Reifenberger J, Reifenberger G, (2008) Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. Int J Cancer 122: 2503-2510.
24. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, et al. (2006) Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 119: 792-800.
25. Cooper GM, Stone EA, Asimenos G, Green ED, Batzoglou S, et al. (2005) Distribution and intensity of constraint in mammalian genomic sequence. Genome Res 15: 901-913.
26. Hampson L, He XT, Oliver AW, Hadfield JA, Kemp T, et al. (2009) Analogues of Y27632 increase gap junction communication and suppress the formation of transformed NIH3T3 colonies. Br J Cancer 101: 829-839.
27. Bagchi A, Mills AA, (2008) The quest for the 1p36 tumor suppressor. Cancer Res 68: 2551-2556.
28. Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
29. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
30. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331: 768-772.
31. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, et al. (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331: 435-439.
32. Bralten L, Kloosterhof N, Balvers R, Sacchetti A, Lapre L, et al. (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 69: 455-463.
33. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
34. Xu W, Yang H, Liu Y, Yang Y, Wang P, et al. (2011) Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of alpha-Ketoglutarate-Dependent Dioxygenases. Cancer Cell 19: 17-30.
35. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
36. Taby R, Issa JP, (2010) Cancer epigenetics. CA Cancer J Clin 60: 376-392.